Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A

European Journal of Pharmacology

Volumn 314, Issue 1-2, 1996, Pages 51-59

  Cho, Seongeun ^a   Duchemin, Anne Marie ^a   Neff, Norton H ^a   Hadjiconstantinou, Maria ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

aromatic L amino acid decarboxylase; dopamine; modulation; monoamine oxidase; striatum; tyrosine hydroxylase

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CLORGYLINE; DOPAMINE; HOMOVANILLIC ACID; MESSENGER RNA; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PHENETHYLAMINE; PTERIDINE; RADIOISOTOPE; SELEGILINE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEAMINATION; DOPAMINE METABOLISM; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BRAIN; CLORGYLINE; MALE; MICE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; TYROSINE 3-MONOOXYGENASE;

EID: 0030600511     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00530-4     Document Type: Article

References (50)

1. Azzaro, A.J., J. King, J. Kotzuk, D.D. Schoepp, J. Frost and S. Schochet, 1985, Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism, J. Neurochem. 45, 949.
2. Bach, A.W., N.C. Lan, D.L. Johnson, C.W. Abell, M.E. Bembenek, S.W. Kwan, P.H. Seeburg and J.C. Shih, 1988, cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties, Proc. Natl. Acad. Sci. USA 85, 4934.
3. Butcher, S.P., I.S. Fairbrother, J.S. Kelly and G.W. Arbuthnott, 1990, Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum, J. Neurochem. 55, 981.
4. Chomczynski, P. and N. Sacchi, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal. Biochem. 162, 156.
5. Cohen J. and Neff N.H., 1982, Activation of retinal tyrosine hydroxyalse: tolerance induced by chronic treatment with haloperidol does not modify response to light. J. Pharmacol. Exp. Ther. 221,326
6. Cohen J., P.M. Iuvone and N.H. Neff, 1981, Neuroleptic drugs activate tyrosine hydroxylase in retinal amacrine cells, J. Pharmacol. Exp. Ther. 218, 390.
7. Cohen, J., M. Hadjiconstantinou and N.H. Neff, 1983, Activation of dopamine-containing amacrine cells of retina: light-induced increase of acidic dopamine metabolites, Brain Res. 260, 125.
8. Dyck, L.E., D.A. Durden and A.A. Boulton, 1993, Effects of monoamine oxidase inhibitors on the acid metabolites of some trace amines and of dopamine in the rat striatum, Biochem. Pharmacol. 45, 1317.
9. Eaton, M.J., K.P. Gudehithlu, T. Quach, C.P. Silvia, M. Hadjiconstantinou and N.H. Neff, 1993, Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology, J. Comp. Neurol. 337, 640.
10. Engberg, G., T. Elebring and H. Nissbrandt, 1991, Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons, J. Pharmacol. Exp. Ther. 259, 841.
11. Fletcher, G.H. and M.S. Starr, 1987, Behavioral evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat, Eur. J. Pharmacol. 138, 407.
12. Garrett, M.C. and P. Soares-da-Silva, 1990. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat, Neuropharmacology 29, 875.
13. Green, A.R., B.D. Mitchell, A.F. Tordoff and M.B. Youdim, 1977, Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine, Br. J. Pharmacol. 60, 343.
14. Grimsby, J., N.C. Lan, R. Neve, K. Chen and J.C. Shih, 1990, Tissue distribution of human monoamine oxidase A and B mRNA, J. Neurochem. 55, 1166.
15. Guidotti, A., K. Gale, G. Toffano and F.M. Vargas, 1978, Tolerance to tyrosine hydroxylase activation in n. accumbens and striatum after repeated injections of "classical" and "atypical" antischizophrenic drugs, Life Sci. 23, 501.
16. Hadjiconstantinou, M., Z.L. Rossetti, C. Silvia, D. Krajnc and N.H. Neff, 1988, Aromatic L-amino acid decarboxylase activity of the rat retina is modulated in vivo by environmental light, J. Neurochem. 51, 1560.
17. Hadjiconstantinou, M., T.A. Wemlinger, C.P. Silvia, J. Hubble and N.H. Neff, 1993, Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopaminergic receptors, J. Neurochem. 60, 2175.
18. Hadjiconstantinou, M., J.P. Hubble, T.A. Wemlinger and N.H. Neff, 1994, Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists, J. Pharmacol. Exp. Ther. 270, 639.
19. Hadjiconstantinou, M., Z.V. Rossetti, T.A Wemlinger and N.H. Neff, 1995, Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity, Eur. J. Pharmacol. Mol, Pharmacol. Sect. 289, 97.
20. Hall, D.W., B.W. Logan and G.H. Parsons, 1969, Further studies on the inhibition of monoamine oxidase by M and B 9302 (clorgyline). I. Substrate specificity in various mammalian species, Biochem. Pharmacol. 18, 1447.
21. Hovevey-Sion, D., I.J. Kopin, R.W. Stull and D.S. Goldstein, 1989, Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma, Neuropharmacology 28, 791.
22. Iuvone, P.M., C.L. Galli and N.H. Neff, 1978a. Light stimulates tyrosine hydroxylase activity and dopamine synthesis in retina amacrine neurons, Science 202, 901.
23. Iuvone, P.M., C.L. Galli and N.H. Neff, 1978b, Retinal tyrosine hydroxylase: comparison of short-term and long-term stimulation by light, Mol. Pharmacol. 14, 1212
24. Iuvone, P.M. and A.L. Rauch, 1983, Alpha2-adrenergic receptors influence tyrosine hydroxylase activity in retinal dopamine neurons, Life Sci. 33, 2455.
25. Javoy, F., Y. Agid, D. Bouvet and J. Glowinski, 1972, Feedback control of dopamine synthesis in dopaminergic terminals of the rat striatum, J. Pharmacol. Exp. Ther. 182, 454.
26. Johnston, J.P., 1968, Some observations upon a new inhibitor of monoamine oxidase in brain tissue, Biochem. Pharmacol. 17, 1285.
27. Knoll, J., 1983, Deprenyl (selegiline): the history of its development and pharmacological action, Acta Neurol. Scand. Suppl. 95, 57.
28. Knoll, J. and K. Magyar, 1972, Some puzzling pharmacological effects of monoamine oxidase inhibitors, Adv. Biochem. Psychopharmacol. 5, 393.
29. Li, X.-M., A.V. Juorio, I.A. Paterson and M.Y. Zhu, 1992a, Specific irreversible monoamine oxidase B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells, J. Neurochem. 59, 2324.
30. Li, X.-M., A.V. Juorio, I.A. Paterson, W. Walz, M.-Y. Zhu and A.A. Boulton, 1992b, Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells, J. Neurochem. 59, 1172.
31. Lowry, O.H., N.J. Rosebrough, A.L. Farr and R.J. Randall, 1951, Protein measurement with the Folin phenol reagent, J. Biol. Chem. 193, 265.
32. Melamed, E., F. Hefti and R.J. Wurtman, 1980, L-3,4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotonergic input, J. Neurochem. 34, 1753.
33. Murrin, L.C., III V.H.N. Morgenroth and R.H. Roth, 1974, Activation of striatal tyrosine hydroxylase by increase of impulse flow, Pharmacologist 16, 213.
34. Neff, N.H. and E. Costa, 1968, Application of steady-state kinetics to the study of catecholamine turnover after monoamine oxidase inhibition or reserpine administration, J. Pharmacol. Exp. Ther. 160, 40.
35. Neff, N.H. and H.Y. Yang, 1974, Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci. 14, 2061.
36. O'Carroll, A.M., C.J. Fowler, J.P. Phillips, I. Tobbia and K.F. Tipton, 1983. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions, Naunyn-Schmiedeberg's Arch. Pharmacol. 322, 198.
37. Paterson, A.I., A.V. Juorio, M.D. Berry and M.Y. Zhu, 1991, Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum, J. Pharmacol. Exp. Ther. 258, 1019.
38. Rossetti, Z., D. Krajnc, N.H. Neff and M. Hadjiconstantinou, 1989, Modulation of retinal aromatic L-amino acid decarboxylase via alpha 2 adrenoceptors, J. Neurochem. 52, 647.
39. Rossetti, Z.L., C.P. Silvia, D. Krajnc, N.H. Neff and M. Hadjiconstantinou, 1990, Aromatic L-amino acid decarboxylase is modulated by D1 dopamine receptors in rat retina, J. Neurochem. 54, 787.
40. Schoepp, D.D. and A.J. Azzaro, 1981, Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition, J. Neurochem. 37, 527
41. Urwyler, S. and J.P. Von Wartburg, 1980, Studies on the subcellular localization of monoamine oxidase types A and B and its importance for the deamination of dopamine in the rat brain, Biochem. Pharmacol. 29, 3067.
42. Vrana S.L., A. J. Azzaro and K.E. Vrana, 1992. Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway, J. Pharmacol. Exp. Ther. 41, 839.
43. Waldmeier, P.C., A. Delini-Stula and L. Maitre, 1976, Preferential deamination of dopamine by an A type monoamine oxidase in rat brain, Naunyn-Schmiedeberg's Arch. Pharmacol. 292, 9.
44. Yang, H.Y. and N.H. Neff, 1973, Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain, J. Pharmacol. Exp. Ther. 187, 365.
45. Young, E.A., N.H. Neff and M. Hadjiconstantinou, 1993, Evidence for a cyclic AMP-mediated increase of aromatic L-amino acid decarboxylase activity in the striatum and midbrain, J. Neurochem. 60, 2331.
46. Young, E.A., N.H. Neff and M. Hadjiconstantinou, 1994, Phorbol ester administration transiently increases aromatic L-amino acid decarboxylase activity of the mouse striatum and midbrain, J. Neurochem. 63, 694.
47. Youdim, B.M.H., E. Heldman, H.B. Pollard, P. Fleming and E. McHugh, 1986, Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells, Neuroscience 19, 1311.
48. Zhu, M.Y., A.V. Juorio, I.A. Paterson and A.A. Boulton, 1992, Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain, J. Neurochem. 58, 637.
49. Zhu, M.-Y., A.V. Juorio, I.A. Paterson and A.A. Boulton, 1993, Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopaminergic receptors, Eur. J. Pharmacol. 238, 157.
50. Zivkovic, B., A. Guidotti and E. Costa, 1974, Effects of neuroleptics on striatal tyrosine hydroxylase: changes in affinity for the pteridine cofactor, Mol. Pharmacol. 10, 727.